EA031493B9 - Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл) - Google Patents

Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл)

Info

Publication number
EA031493B9
EA031493B9 EA201591932A EA201591932A EA031493B9 EA 031493 B9 EA031493 B9 EA 031493B9 EA 201591932 A EA201591932 A EA 201591932A EA 201591932 A EA201591932 A EA 201591932A EA 031493 B9 EA031493 B9 EA 031493B9
Authority
EA
Eurasian Patent Office
Prior art keywords
lymphoma
nhl
hodgkin
prophylaxis
treatment
Prior art date
Application number
EA201591932A
Other languages
English (en)
Other versions
EA201591932A1 (ru
EA031493B1 (ru
Inventor
Нингшу Лию
Катя Хайке
Юлиане Паул
Антье Маргрет Венгнер
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201591932A1 publication Critical patent/EA201591932A1/ru
Publication of EA031493B1 publication Critical patent/EA031493B1/ru
Publication of EA031493B9 publication Critical patent/EA031493B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Настоящее изобретение относится к комбинациям для лечения или профилактики неходжкинской лимфомы (НХЛ) из а) соединения 2,3-дигидроимидазо[1,2-с]хиназолина, а именно 2-амино-N-[7-метокси-8-(3-морфолин-4-илпропокси)-2,3-дигидроимидазо[1,2-с]хиназолин-5-ил]пиримидин-5-карбоксамида и b) одного или нескольких дополнительных активных агентов, выбранных из группы, состоящей из PI3Kδ-селективного ингибитора GS-1101, ингибитора BTK ибрутиниб, IKK ингибитора BAY соединение В и рефаметиниба (refametinib) (BAY 86-9766 (RDEA-119)), причем неходжкинская лимфома (НХЛ) выбрана из лимфомы терапии первой линии, второй линии, рецидивной, рефрактерной, индолентной или агрессивной неходжкинской лимфомы (НХЛ), в частности фолликулярной лимфомы (ФЛ), хронической лимфоцитарной лейкемии (ХЛЛ), лимфомы маргинальной зоны (ЛМЗ), диффузной В-крупноклеточной лимфомы (ДВККЛ), мантийноклеточной лимфомы (МКЛ), трансформированной лимфомы (ТЛ) или периферической Т-клеточной лимфомы (ПТКЛ); к фармацевтической композиции для лечения или профилактики неходжкинской лимфомы (НХЛ), содержащей комбинацию а) указанного соединения и b) указанных одного или нескольких дополнительных активных агентов.
EA201591932A 2013-04-08 2014-04-04 Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл) EA031493B9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13162710 2013-04-08
EP13184240 2013-09-13
PCT/EP2014/056768 WO2014166820A1 (en) 2013-04-08 2014-04-04 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

Publications (3)

Publication Number Publication Date
EA201591932A1 EA201591932A1 (ru) 2016-04-29
EA031493B1 EA031493B1 (ru) 2019-01-31
EA031493B9 true EA031493B9 (ru) 2019-12-18

Family

ID=50439383

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201591932A EA031493B9 (ru) 2013-04-08 2014-04-04 Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл)
EA201792650A EA037577B1 (ru) 2013-04-08 2014-04-04 ПРИМЕНЕНИЕ 2-АМИНО-N-[7-МЕТОКСИ-8-(3-МОРФОЛИН-4-ИЛПРОПОКСИ)-2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИН-5-ИЛ]ПИРИМИДИН-5-КАРБОКСАМИДА ИЛИ ЕГО ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМОЙ СОЛИ ИЛИ ГИДРАТА И ФАРМАЦЕВТИЧЕСКОЙ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ УКАЗАННОЕ СОЕДИНЕНИЕ, ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ НЕХОДЖКИНСКОЙ ЛИМФОМЫ (НХЛ)

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201792650A EA037577B1 (ru) 2013-04-08 2014-04-04 ПРИМЕНЕНИЕ 2-АМИНО-N-[7-МЕТОКСИ-8-(3-МОРФОЛИН-4-ИЛПРОПОКСИ)-2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИН-5-ИЛ]ПИРИМИДИН-5-КАРБОКСАМИДА ИЛИ ЕГО ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМОЙ СОЛИ ИЛИ ГИДРАТА И ФАРМАЦЕВТИЧЕСКОЙ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ УКАЗАННОЕ СОЕДИНЕНИЕ, ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ НЕХОДЖКИНСКОЙ ЛИМФОМЫ (НХЛ)

Country Status (28)

Country Link
US (2) US9999623B2 (ru)
EP (1) EP2983669B1 (ru)
JP (1) JP6368353B2 (ru)
KR (1) KR102304108B1 (ru)
CN (1) CN105263497B (ru)
AP (1) AP2015008750A0 (ru)
AU (1) AU2014253348B2 (ru)
BR (1) BR112015025304B1 (ru)
CA (1) CA2908776C (ru)
CL (1) CL2015002978A1 (ru)
CR (1) CR20150523A (ru)
CU (1) CU24400B1 (ru)
DO (1) DOP2015000256A (ru)
EA (2) EA031493B9 (ru)
ES (1) ES2708350T3 (ru)
HK (1) HK1220121A1 (ru)
IL (1) IL241543B (ru)
JO (1) JOP20140141B1 (ru)
MX (1) MX2015014171A (ru)
MY (1) MY192626A (ru)
NI (1) NI201500148A (ru)
PE (1) PE20151780A1 (ru)
PH (1) PH12015502317A1 (ru)
SG (2) SG11201507265XA (ru)
TN (1) TN2015000452A1 (ru)
TW (2) TWI675663B (ru)
UA (2) UA119537C2 (ru)
WO (1) WO2014166820A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
EP3077003A1 (en) 2013-12-03 2016-10-12 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016087488A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Administration regime for aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives
WO2016087490A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
US10406162B2 (en) 2015-03-09 2019-09-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-C]quinazoline-containing combinations
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
AU2016286548B2 (en) 2015-07-02 2020-12-10 Acerta Pharma B.V. Solid forms and formulations of (S)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo(1,5-a)pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
AU2017214230A1 (en) * 2016-02-01 2018-08-09 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
SG11201806512VA (en) * 2016-02-01 2018-08-30 Bayer Pharma AG Copanlisib biomarkers
CA3016584A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
CN109906224B (zh) * 2016-06-20 2022-02-25 诺华股份有限公司 三唑吡啶化合物及其应用
CN109790166A (zh) * 2016-06-20 2019-05-21 诺华股份有限公司 咪唑并吡啶化合物用于治疗癌症
CA3037626A1 (en) * 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
BR112019023632A2 (pt) * 2017-05-18 2020-08-18 Jiangsu Hengrui Medicine Co., Ltd. uso do inibidor de ezh2 combinado com o inibidor de btk na preparação de fármacos para tratamento de tumor
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
KR20200052901A (ko) * 2017-09-13 2020-05-15 광동 오포 모바일 텔레커뮤니케이션즈 코포레이션 리미티드 데이터 처리 방법, 단말기 디바이스 및 네트워크 디바이스
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
US20230029385A1 (en) * 2019-10-15 2023-01-26 Bayer Aktiengesellschaft 2-methyl-aza-quinazolines
JP7440360B2 (ja) 2020-06-30 2024-02-28 東日本旅客鉄道株式会社 山形鋼材の研磨装置
WO2022199373A1 (zh) * 2021-03-26 2022-09-29 上海璎黎药业有限公司 一种喹唑啉化合物及药物组合物的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070150A1 (en) * 2006-12-05 2008-06-12 Bayer Schering Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2012062748A1 (en) * 2010-11-11 2012-05-18 Bayer Pharma Aktiengesellschaft Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2012121953A1 (en) * 2011-03-08 2012-09-13 The Trustees Of Columbia University In The City Of New York Methods and pharmaceutical compositions for treating lymphoid malignancy
WO2013006443A2 (en) * 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
WO2013169858A1 (en) * 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1400959A (en) 1919-04-26 1921-12-20 Ste Chim Usines Rhone Process and apparatus for carrying out chemical reactions by catalysis
US1364099A (en) 1919-09-10 1921-01-04 Flannery Bolt Co Staybolt structure for boilers
US1400975A (en) 1920-10-11 1921-12-20 Page Henry Benjiman Dirigible headlight for motor-vehicles
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JP2003277383A (ja) * 2002-03-14 2003-10-02 Bayer Ag 光学活性ピリジン誘導体およびそれを含む医薬
UA82205C2 (en) 2002-09-30 2008-03-25 Байер Фармасьютикалз Корпорейшн Fused azole-pyrimidine derivatives
WO2009091550A2 (en) 2008-01-14 2009-07-23 Bayer Healthcare Llc Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
MA34158B1 (fr) 2010-04-16 2013-04-03 Bayer Ip Gmbh Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée
AU2011251032B2 (en) 2010-05-14 2015-07-23 Lg Electronics Inc. Method for allocating resources in a wireless communication system and a device for the same
JP5790016B2 (ja) 2011-02-18 2015-10-07 コベルコ建機株式会社 ハイブリッド建設機械
ES2590778T3 (es) * 2011-02-28 2016-11-23 Calitor Sciences, Llc Compuestos de quinolina sustituida
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
US8993891B2 (en) 2012-06-28 2015-03-31 Thomas & Betts International, Inc. Lift and pivot grommet
JP6499657B2 (ja) 2013-12-03 2019-04-10 バイエル ファーマ アクチエンゲゼルシャフト Ｐｉ３ｋ阻害剤の組み合わせ
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
US10406162B2 (en) 2015-03-09 2019-09-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-C]quinazoline-containing combinations
EP3268005A1 (en) 2015-03-09 2018-01-17 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070150A1 (en) * 2006-12-05 2008-06-12 Bayer Schering Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2012062748A1 (en) * 2010-11-11 2012-05-18 Bayer Pharma Aktiengesellschaft Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2012121953A1 (en) * 2011-03-08 2012-09-13 The Trustees Of Columbia University In The City Of New York Methods and pharmaceutical compositions for treating lymphoid malignancy
WO2013006443A2 (en) * 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
WO2013169858A1 (en) * 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
N. LIU, B. R. ROWLEY, C. O. BULL, C. SCHNEIDER, A. HAEGEBARTH, C. A. SCHATZ, P. R. FRACASSO, D. P. WILKIE, M. HENTEMANN, S. M. WIL: "BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110 and p110 Activities in Tumor Cell Lines and Xenograft Models", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 12, no. 11, 1 November 2013 (2013-11-01), US, pages 2319 - 2330, XP055121310, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-12-0993-T *

Also Published As

Publication number Publication date
PE20151780A1 (es) 2015-12-20
PH12015502317A1 (en) 2016-02-10
TW201924690A (zh) 2019-07-01
CA2908776A1 (en) 2014-10-16
BR112015025304B1 (pt) 2022-09-27
UA119537C2 (uk) 2019-07-10
CR20150523A (es) 2016-01-29
CL2015002978A1 (es) 2016-04-15
MX2015014171A (es) 2015-12-16
TWI675663B (zh) 2019-11-01
TW201517909A (zh) 2015-05-16
EA201792650A1 (ru) 2018-04-30
TN2015000452A1 (en) 2017-04-06
US9999623B2 (en) 2018-06-19
UA122822C2 (uk) 2021-01-06
JP6368353B2 (ja) 2018-08-01
JOP20140141B1 (ar) 2021-08-17
NZ712033A (en) 2021-03-26
DOP2015000256A (es) 2015-12-31
HK1220121A1 (zh) 2017-04-28
MY192626A (en) 2022-08-29
ES2708350T3 (es) 2019-04-09
KR102304108B1 (ko) 2021-09-23
SG11201507265XA (en) 2015-10-29
CU24400B1 (es) 2019-04-04
SG10201710539QA (en) 2018-01-30
EP2983669B1 (en) 2018-10-24
EA037577B1 (ru) 2021-04-16
EA201591932A1 (ru) 2016-04-29
AU2014253348A1 (en) 2015-10-08
KR20150138858A (ko) 2015-12-10
AU2014253348B2 (en) 2019-05-23
IL241543B (en) 2019-08-29
NI201500148A (es) 2015-11-30
WO2014166820A1 (en) 2014-10-16
AP2015008750A0 (en) 2015-09-30
JP2016515601A (ja) 2016-05-30
TWI689307B (zh) 2020-04-01
EP2983669A1 (en) 2016-02-17
CA2908776C (en) 2021-08-10
CN105263497A (zh) 2016-01-20
BR112015025304A2 (pt) 2017-07-18
US20160058770A1 (en) 2016-03-03
EA031493B1 (ru) 2019-01-31
CU20150140A7 (es) 2016-10-28
CN105263497B (zh) 2019-04-30
US10226469B2 (en) 2019-03-12
US20180193349A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
EA031493B9 (ru) Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл)
NZ772688A (en) The use of inhibitors of bruton’s tyrosine kinase (btk)
CL2012000163A1 (es) Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras.
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
MX2009009304A (es) Inhibidores de cinasa pim y metodos para su uso.
CL2008001374A1 (es) Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
UY30892A1 (es) Inhibidores de la actividad akt
CR20110261A (es) COMPUESTOS PIRAZOLO[1,5-a]PIRIMIDINA SUSTITUIDA COMO IHNIBIDORES DE TRK CINASA
EA201100425A1 (ru) Производные пиколинамида в качестве ингибиторов киназы
MY183661A (en) Treatment of cancer with tor kinase inhibitors
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
HRP20192100T1 (hr) Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe
EA201890142A1 (ru) Замещенные пиримидиновые обратные ингибиторы bmi-1
EA201100426A1 (ru) Бициклические ингибиторы киназы
MX2009009117A (es) Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
CY1112478T1 (el) Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες
EA201001412A1 (ru) Ингибиторы киназы pim и способы их применения
NZ741293A (en) Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX362939B (es) Derivados de (aza-)isoquinolinona.
MX2014002967A (es) Antagonistas de los productos del agrupamiento de unigenes hs.459642 para la inhibicion de la proliferacion, del desarrollo o de la diferenciacion de las celulas madre incluyendo las celulas madre cancerosas.
CL2011001445A1 (es) Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias
MY169738A (en) Fused bicyclic pyrimidines
WO2014186623A3 (en) Methods and compositions for the treatment of a chagas disease
PH12015500185B1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KG TJ TM

TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM